SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Blue Sanofi sign on building in Germany at night
Drug Development
Sanofi Axes Lung Cancer ADC After Phase III Trial Failure
The company is ending its program evaluating antibody-drug conjugate tusamitamab ravtansine after a non-small cell lung cancer trial did not meet a primary endpoint.
December 21, 2023
 · 
2 min read
 · 
Tyler Patchen
Southern Research's headquarters in Birmingham Ala
Drug Development
A World War II-Era Company Reshapes Itself as a Biotech Powerhouse
Now designated as a Tech Hub by the White House, Alabama’s nonprofit Southern Research is winnowing its focus and investing in healthcare solutions.
December 20, 2023
 · 
6 min read
 · 
Tyler Patchen
Pictured: uniQure headquarters in Amsterdam
Drug Development
UniQure Touts Phase I/II Results for Huntington’s Disease Candidate, Wall Street Balks
Gene therapy company uniQure announced Tuesday “ongoing evidence” of a clinical benefit for its Huntington’s disease treatment. However, investors were not impressed as the stock dropped nearly 20%.
December 20, 2023
 · 
2 min read
 · 
Tyler Patchen
Drug Development
Every move you make: Biopharma industry under heavy scrutiny
On this episode of the Weekly: Biden administration puts pressure on the biopharma industry; renewed interest in psychedelics after MindMed announces LSD-based candidate meets primary endpoint; bluebird changes its tune.
December 20, 2023
 · 
1 min read
 · 
Lori Ellis
Pictured: Merck building and sign in Silicon Valley
Drug Development
Merck Secures FDA Decision Date for Pneumococcal Vaccine, Race Heats Up with Pfizer
The competition between Merck’s pneumococcal vaccine and Pfizer’s Prevnar series of vaccines is intensifying after the regulator granted priority review to the former’s BLA for V116.
December 20, 2023
 · 
2 min read
 · 
Tyler Patchen
Bernd Weissbrod/picture alliance via Getty Images
Policy
German Court Nullifies CureVac’s Patent Case Against BioNTech
A court in Germany on Tuesday nullified one of CureVac’s intellectual property rights in a patent case against BioNTech. However, court proceedings involving seven other patent rights will continue.
December 20, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: GSK's office in Poznan, Poland/iStock, W
Business
GSK Inks Potential $1.7B ADC Deal with China’s Hansoh Pharma
With an upfront payment of $185 million, GSK on Wednesday added another exclusive antibody-drug conjugate license agreement with China-based Hansoh Pharma.
December 20, 2023
 · 
2 min read
 · 
Tyler Patchen
Q&A: JLL Analyst Mark Bruso on Biopharma Venture Capital Activity
With uncertainty rocking the venture capital market in the biotech and pharma industry, analysts from JLL give their thoughts on what the market looks like and where it may be heading.
December 19, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Gilead's headquarters in Silicon Valley/
Business
Gilead, Compugen Ink Potential $848M Deal for Preclinical Immunotherapy
Israel-based cancer immunotherapy company Compugen will receive $60 million upfront from Gilead for the license to its antibody, which blocks the interaction between the IL-18 binding protein and IL-18.
December 19, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Eli Lilly's biotechnology center in San
Drug Development
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
While the candidate was effective in Phase III results, Point’s stock price fell following the announcement.
December 18, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Downward arrow in graph showing stock price dropping
Drug Development
Structure’s GLP-1 Drug Shows Efficacy in Phase IIa but Faces Stock Falloff
A GLP-1-based drug from Structure Therapeutics shows clinical promise but not enough for some on Wall Street.
December 18, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bristol Myers Squibb building in Munich/
Drug Development
Bristol Myers Squibb Puts Kibosh on Trials of Colorectal Cancer Candidate
BMS will halt a trial investigating the Opdulag combination in colorectal cancer after determining that it would not hit its primary endpoint.
December 18, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pieces of paper with chemical structures
Drug Development
MindMed Posts Positive Phase II Results for LSD-Based Treatment for Anxiety
The biotech reported topline data from a mid-stage study of MM-120, its LSD-based drug, in patients with generalized anxiety disorder.
December 15, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: GSK's headquarters in London
Policy
EMA Committee Votes Against Renewing Marketing Authorization for GSK’s Blenrep
A European Medicine Agency panel on Friday reaffirmed its decision not to renew the conditional marketing authorization for GSK’s multiple myeloma drug Blenrep.
December 15, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Merck Headquarters/iStock, JHVEPhoto
FDA
FDA Approves Merck’s Welireg for Treating Renal Cell Carcinoma
Merck’s HIF-2α inhibitor Welireg has been approved by the FDA to treat advanced renal cell carcinoma after treatment with PD-1 or PD-L1 and VEGF-TKI-based therapies.
December 15, 2023
 · 
2 min read
 · 
Tyler Patchen
Load More